Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00828308 · ClinicalTrials.gov registry record · Phase 2

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

A Phase 2 study, sponsored by Brown University.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target

NCT00828308: Completed Phase 2 study, sponsored by Brown University.

NCT00828308 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00828308, a Phase 2 study, has completed, sponsored by Brown University.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)

Primary Outcome

Decrease in PSA:number of participants with decreased serum PSA level after 12 weeks of ixabepilone

Interventions

  • DRUG Ixabepilone
  • PROCEDURE Prostatectomy

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2009-02
Est. Completion 2016-12
Phase Phase 2
Brown University

231 total trials

What the finished NCT00828308 record still lists

NCT00828308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Ixabepilone is the first listed.

NCT00828308 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00828308 about?

NCT00828308 is a clinical study titled "Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer". Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)

What is the current status of trial NCT00828308?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-02. Estimated completion is 2016-12.

What interventions are being tested in trial NCT00828308?

The interventions under investigation include: Ixabepilone (DRUG), Prostatectomy (PROCEDURE).

Who is sponsoring clinical trial NCT00828308?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00828308's enrollment target sits among peer trials

16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00828308, the US trial registry maintained by the National Library of Medicine. NCT00828308 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.